Member Info for howdlep

Hi Tyke,

While it is considered best practice for directors to attend an Annual General Meeting (AGM) to remain accountable to shareholders, there is no strict legal requirement under the UK Companies Act 2006 for them to be physically present.

That said, outside of a Covid type situation, I doubt they would initiate coverage.

I am personally unable to attend this AGM, but I certainly would like to in the future.

AI suggests that:-

Shareholders generally have the right to submit questions prior to an Annual General Meeting (AGM). While specific instructions for the 2026 AGM will be detailed in the formal Notice of Meeting sent to you at least 21 clear days in advance, the following general procedures for UK listed companies and IBAI typically apply:-

Submission Formats

Shareholders usually have several ways to submit questions before the meeting:

Email: Questions are often sent directly to the Company Secretary or a dedicated investor relations email address.

Online Portal: Many companies use shareholder portals (like those managed by registrars such as Computershare) where you can submit questions alongside your proxy vote.

Written Letter: Hard copy questions can be sent to the company's registered office, addressed to the Company Secretary.

Typical Timelines & Procedures

Deadline: Most companies request that pre-submitted questions arrive at least 48 hours before the meeting, though some may set an earlier informal "deadline" to allow for grouping of themes.

Answering Process: The Board may choose to answer pre-submitted questions during the AGM itself, publish a Q&A document on the IBAI Investor Relations website beforehand, or respond directly in writing.

Auditor Questions: For questions specifically about the audit, you have a statutory right to submit these in writing to the auditor via the company at least five business days before the AGM.

Actionable Tips

Check the Notice: Your primary source for the exact email address or portal link will be the Notice of 2026 Annual General Meeting, which will be posted to your registered address and uploaded to the London Stock Exchange news service.

Proxy Voting: Even if you submit a question, you should still submit your Proxy Form in advance to ensure your vote is counted, as most outcomes are determined by these pre-submitted votes.

Beneficial Owners: If you hold shares through a nominee (like a broker app), you may need to ask your broker to submit the question on your behalf or provide a "letter of representation" to participate personally.

Phil

P.S. a very interesting AGM result from PYC has now been released via RNS.

Tyke,

It may help the confusion if you say:-

IBAI is the ticker code for Imaging Biometrics Ltd, a healthcare company listed on the London Stock Exchange (LSE).The company, formerly known as IQ-AI Limited, provides clinical treatments and medical imaging diagnostic software.

Phil

L2 very strong. 0.8p paid for 668k, 3 (900k)0.6 v 2 (600k) 0.8p

Finals imminent highlighting a small maiden profit. But it's all about the data publication and the revenue growth in the forward looking statement.

A good point Max and the answer is no. However, they could issue them at the nominal value of 1p and pay the balance out of company reserves. If we had any reserves!

Or they could issue twice the options at 1p. Either way, I want the hard earned salary paid in cash and for a small profit still to be declared in the annual report.

Max,

Volume is pretty much non existent so the percentage gain/loss shown by the likes of investing dot com is of no importance. However, as Tyke knows only too well, the days gain is based on the price of the last trade of the day. So, in the case of yesterday, it relates to the 175k sell at 0.4564p. But to confuse matters, there was a tiny after hours buy of 1367 @ 0.50p, so today's movement is zero, given that we have only had the 40k buy 0.50p.

When we have a volume day of 5m it may be worth thinking about, but at the current price of 0.5p that's only £25k.

As for keeping the share price low and restricting the shares you can buy, we are currently 3v1. All irrelevant given the tiny volumes and the MM's will react quickly to any increase. However, as a rule 3 (900k) v 1 (300k) is suggesting they would prefer to be buying than selling, so lets hope there is good news in the annual report.

I am more interested in the AGM resolutions as I do not want TB or the board receiving shares in lieu of salary. I am sure you have worked out that a £100k salary would equate to 20m shares at 0.5p. That is not acceptable whatsoever and I would urge all shareholders to vote against any such resolution.

It is one thing to cancel and re price previous options, as with MS, but new options from here on in should be performance related and a multiple of the current price.

There needs to be a clear plan to attract new investors, rather than just issue a series of tweets. As good as they may be, investors are not understanding the business or what they have to offer. That has to change now and we certainly do not need new board members who are not prepared to buy shares on the open market, while at the same time approving remuneration packages.

But let's see how the annual report reads, in relation to the small profit and more importantly, the forward looking statement.

Phil

Summarise the different ways the GaM phase I trial data could be used by Imaging Biometrics and attribute an estimated value to each scenario?

Based on recent corporate updates, Imaging Biometrics (IBAI) has shifted its focus towards high-margin imaging software, while treating the phase I Gallium Maltolate (GaM) data as a high-value asset for future licensing or partnership.

The company successfully completed the Phase 1 trial with promising efficacy data—specifically showing an overall survival of 32 months compared to the 8–9 month average for glioblastoma patients.

Here is a summary of the ways the Phase I GaM trial data can be used and their estimated values:

1. Monetization via Licensing or Partnership (High Value)

Usage: Utilizing the completed Phase I data, along with Orphan Drug and FDA Fast Track Designations, to secure a licensing deal or partnership with a larger pharmaceutical or biotech company to fund Phase II/III trials.

Value: High. This is considered the primary "strategic optionality" value. The data preserves the ability to unlock the compound's value without Bearing the high cost of further development internally.

2. Validation of Imaging Software (Medium Value)

Usage: Leveraging the trial imaging data (e.g., FTB maps, QSMetric) to demonstrate the efficacy and superiority of IB's commercial software in monitoring treatment response, thereby driving adoption of their imaging products.

Value: Medium-to-High. By using the trial to prove that IB's software can precisely measure drug effects (e.g., distinguishing tumor from treatment effects), it adds a "turnkey" monitoring solution value to their existing commercial portfolio.

3. Expanded Access Program (EAP) and Real-World Data (Low-to-Medium Value)

Usage: Using the data to support an FDA-approved EAP (compassionate use) for patients, allowing the gathering of real-world data and ongoing clinical interaction.

Value: Medium. While not a direct high-margin product sale, it maintains clinical engagement and gathers data that supports the "breakthrough" nature of the compound.

4. Supporting Third-Party Pediatric Trials (Strategic Value)

Usage: Monitoring the independent GABRIEL pediatric trial using GaM for insights, using their own phase I data to support this external work.

Value: Low (Immediate) / High (Long-term). It keeps the drug active and scientifically relevant without IB bearing the cost of study management, enhancing the potential for future pediatric indication.

Summarise the benefits of yesterday's RNS award of a new $3m NIH grant to Dr. Mona Gizawiy at the Medical Collage of Wisconsin (MCW) and a sub award to Imaging Biometrics, in relation to the likelihood of another company advancing the completed phase I GaM trial into a new phase II trial:-

The $3 million NIH R01 grant awarded to Dr. Mona Al-Gizawiy at the Medical College of Wisconsin (MCW), with a sub-award to Imaging Biometrics (IBAI), provides several strategic benefits that directly increase the likelihood of a third party advancing the Gallium Maltolate (GaM) Phase I trial into Phase II:

Non-Dilutive Pre-clinical Validation:

The grant funds a five-year project to study GaM in combination with radiation therapy for aggressive pediatric brain cancers. This provides critical data on synergistic effects without requiring further capital from IBAI or a potential partner.

Expansion into Pediatric Oncology:

By moving into pediatric indications, the asset's addressable market and value proposition are significantly broadened. This diversification makes GaM a more attractive "multi-indication" candidate for larger pharmaceutical companies.

Enhanced De-risking via Imaging:

IBAI’s role as a sub-award recipient involves using its quantitative imaging biomarkers to monitor treatment response. Proving that GaM’s efficacy can be precisely measured via IBAI's software provides a "turnkey" monitoring solution for any company taking the drug into Phase II.

Maintained Academic Momentum:

The grant ensures that the primary investigators from the Phase I trial (at MCW) remain actively engaged with the drug. A "warm" clinical team with ongoing NIH funding is a major operational advantage for a partner looking to launch a new trial quickly.

Strategic Optionality:

Because IBAI recently pivoted to focus on its high-margin software business, this grant keeps the drug asset active and scientifically relevant. It allows IBAI to wait for a high-value partnership or licensing deal while the NIH effectively pays for the ongoing "bench" research.

Further thoughts anyone?

Max,

Normality has now returned with:-

2 (600k) 0.45 v 0.60 (600k) 2

2 (600k) 0.40 v 0.65 (600k) 2

plus the deliberately wide quote of

1 (300k) 0.30 v 1.30 (300k) 1

Don't think it was my L2 screen as other stocks seemed to be ok, so perhaps just a very long MM lunch rather than something more sinister!

Phil

L2 appears to have strengthened for no apparent reason, with 2 (600k) v 2 (600k).

Interestingly, have 3 MM's disappeared?

Thoughts anyone

Interesting. I suspect a tick up on bid and offer is coming. Let's see what the next decent buy brings.

Offer ticked up with that 170k buy. Now 4 (1.2m) v 1 (300k) with 1.2m on offer at 0.70. Looking good for a run?

Very low volume obviously, but L2 has strengthened to 3 v 1. Tick up on the offer shortly. However, all will depend on the size and direction of the next decent trade.

Roll on a better volume day on Monday, with good news please.

Today, 27 February 2026, Imaging Biometrics (IBAI) is hosting a live webinar to debut IB Nimble 2.0, a major upgrade to its mobile multidisciplinary team:-

New Features in IB Nimble 2.0

Integrated DICOM Viewing: The most significant update, this allows clinicians to view high-quality medical images directly within the app rather than switching to a desktop workstation.

Enhanced Collaboration: Real-time, secure communication tools for multi-specialty care teams to review cases and make treatment decisions asynchronously.

Scalability & Mobile Access: The platform has been rebuilt on a new codebase to ensure it can scale across large hospital networks while remaining a "lightweight" portable solution.

Customisable Treatment Guidelines: Sites can now tailor the app to their specific clinical protocols and available resources.

As defined by Google AI:-

Based on the most recent grant data from the Musella Foundation, there have been several financial awards specifically directed to Imaging Biometrics (IB) to support the development and access of Gallium Maltolate (GaM).

Musella Foundation Awards to Imaging Biometrics

$4,000 Patient Support Grant (2026): According to the 2026 Grant Awards list, a $4,000 grant was issued to Imaging Biometrics specifically to help patients pay for treatment within the "Expanded Access Program of Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma".

$40,000 Patient Support Grant (2025): For the 2025 calendar year, the Foundation awarded $40,000 to IB for the same project title to assist patients with treatment costs under the iEAP.

$16,500 Fractional Tumor Burden (FTB) Map Grant (2025): An "add-on" grant of $16,500 was awarded to IB to fund the creation of Fractional Tumor Burden Maps for a project led by Dr. Danielle A. Bazer at Cooper University.

$100,000 iEAP Launch Grant (2024): Announced on 2 February 2024, this major grant was provided to support the infrastructure of the intermediate group Expanded Access Program (iEAP), including protocol writing, patient screening, and onboarding.

Initial Phase 1 Award (Prior to 2024): The Foundation provided an initial award to support the ongoing Phase 1 clinical trial conducted at the Medical College of Wisconsin (MCW).

Google AI certainly seems to think so:-

Kirkstall’s Quasi Vivo® aligns with the Nature-discussed, non-animal, in vitro models by using a "milli-fluidic" system to better simulate human interstitial flow and organ-to-organ crosstalk. The platform supports multi-organoid modelling with modular, low-shear chambers designed to enhance predictive accuracy in drug toxicity studies. Detailed information on the system can be found at https://kirkstall.com/

A 625k sell made L2 weak. However, three buys (including one of mine) totalling 900k shares, has levelled things up. Perhaps some are now prepared to accumulate in advance of big news?

One early 450k buy and two smaller sells. L2 identical, so we await further defining trades.

Someone took a very small loss on 185,597 shares. To be fair, they held for ten minutes!

It's been a while since we last saw premium buys. Great to see.

Can't even buy 150k shares. We should be going higher shortly